Trial reportCells2021
Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma.
Trial report in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Development and validation of a diagnostic nomogram integrating anatomical scores and systemic immune-inflammatory biomarkers forFrontiers in immunology · 2026Article
- Distinct Roles of Monocyte Subsets in Cancer.Cells · 2025Review
- Autophagy-related gene BECN1 single nucleotide polymorphisms in diseases.Molecular and cellular biochemistry · 2025Review
- Molecular insights into cell signaling pathways in kidney stone formation.Urolithiasis · 2025Review
- Combination of vascular surgery with novel vascular targeting agents as cancer therapeutics.Frontiers in oncology · 2025Review
- Review
- Mechanisms of autophagy and endoplasmic reticulum stress in the reversal of platinum resistance of epithelial ovarian cancer cells by naringin.Molecular biology reports · 2023Article
- Mild dyslipidemia accelerates tumorigenesis through expansion of Ly6CNature communications · 2022Article
- Review
- CXCR6 expressing T cells: Functions and role in the control of tumors.Frontiers in immunology · 2022Review
- The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.The oncologist · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 15 institutions in 6 countries.
Funding
Abstract
The modulation of subpopulations of pro-angiogenic monocytes (VEGFR-1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.